Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding

Completed

Conditions: Upper Gastrointestinal Bleeding

First Posted Date: 2010-07-01

Last Posted Date: 2011-11-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 300

Registration Number: NCT01155401

Locations: 🇷🇺
Research Site, Moscow, Russian Federation

Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects

Phase 2

Completed

Conditions: Reflux

Interventions: Drug: AZD2516, 5 mg
Drug: AZD2516, 16 mg
Drug: AZD2516, 40 mg
Drug: Placebo

First Posted Date: 2010-07-01

Last Posted Date: 2012-08-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 20

Registration Number: NCT01154634

Locations: 🇳🇱
Research Site, Amsterdam, Netherlands

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

Phase 1

Completed

Conditions: Tolerability
Healthy
Elderly

Interventions: Drug: AZD9742
Drug: Placebo

First Posted Date: 2010-07-01

Last Posted Date: 2010-08-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 12

Registration Number: NCT01154621

Locations: 🇺🇸
Research Site, Springfield, Missouri, United States

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder
Depression

Interventions: Drug: TC-5214
Drug: Placebo

First Posted Date: 2010-06-30

Last Posted Date: 2014-04-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 2409

Registration Number: NCT01153347

Locations: 🇵🇷
Research Site, San Juan, Puerto Rico

A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer).

Completed

Conditions: Non Small Cell Lung Cancer

First Posted Date: 2010-06-30

Last Posted Date: 2015-11-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 589

Registration Number: NCT01153399

Locations: 🇬🇷
Research Site, Volos, Greece

Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Lung Disease
Chronic Obstructive Pulmonary Disease

Interventions: Drug: AZD2423
Drug: AZD2423 Placebo

First Posted Date: 2010-06-30

Last Posted Date: 2015-04-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 71

Registration Number: NCT01153321

Locations: 🇩🇪
Research Site, Hannover, Germany

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Phase 3

Completed

Conditions: MDD
Depression
Major Depressive Disorder

Interventions: Drug: TC-5214
Drug: Placebo

First Posted Date: 2010-06-29

Last Posted Date: 2014-04-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 813

Registration Number: NCT01152554

Locations: 🇵🇷
Research Site, San Juan, Puerto Rico

Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension

Completed

Conditions: Hypertension
Cardiovascular Disease

First Posted Date: 2010-06-29

Last Posted Date: 2011-09-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 50000

Registration Number: NCT01152567

Locations: 🇸🇪
Research Site, VasterAs, Sweden

Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: AZD1656
Drug: Placebo

First Posted Date: 2010-06-29

Last Posted Date: 2012-08-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 224

Registration Number: NCT01152385

Locations: 🇯🇵
Research Site, Tokyo, Japan

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

Phase 2

Terminated

Conditions: Neoplasms
Breast Neoplasms
Breast Cancer

Interventions: Drug: AZD8931
Drug: anastrozole
Drug: Placebo

First Posted Date: 2010-06-28

Last Posted Date: 2014-07-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 482

Registration Number: NCT01151215

Locations: 🇬🇧
Research Site, Wythenshawe, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy